NCT05818306View on ClinicalTrials.gov

A Phase Ia Safety and Tolerability Study of BL-001

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

May 19, 2023

Study Completion Date

June 2, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

BL-001

Live biological product BL-001

DRUG

Placebo

Placebo

Trial Locations (1)

CH-6864

CROSS Research S.A., Arzo

Sponsors

Lead Sponsor

Bloom Science
All Listed Sponsors
lead

Bloom Science

INDUSTRY

NCT05818306 - A Phase Ia Safety and Tolerability Study of BL-001 | Biotech Hunter | Biotech Hunter